stockrowQIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.
- Revenue
- +0.28%
- EPS
- +7.94%
- Free cash flow
- +30.5%
- Total debt
- +13.8%
Quarter to June 2026, against a year earlier
Follow QGEN
Alert me
QIAGEN N.V. (QGEN) Total debt
QIAGEN N.V.'s total debt at the end of fiscal 2025 was $1.7B, up 18.9% from $1.4B in fiscal 2024. At the end of the quarter to 30 June 2026 it was $1.6B. Over the past ten years it has ranged from $1.0B (fiscal 2015) to $2.2B (fiscal 2018); the current reading is higher than 45% of that period. QIAGEN N.V. ranks 14th of 46 Diagnostics & Research companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $1.7B | 18.89% |
| FY2024 | $1.4B | (7.83%) |
| FY2023 | $1.5B | (18.89%) |
| FY2022 | $1.9B | (4.14%) |
| FY2021 | $1.9B | 0.99% |
| FY2020 | $1.9B | 12.68% |
| FY2019 | $1.7B | (21.52%) |
| FY2018 | $2.2B | 22.96% |
| FY2017 | $1.8B | 64.93% |
| FY2016 | $1.1B | 2.20% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $1.6B | (0.18%) |
| Mar 2026 | $1.6B | (0.48%) |
| Dec 2025 | $1.7B | (22.22%) |
| Sep 2025 | $2.1B | 47.31% |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ICLR ICON PLC compare | $3.4B |
| RVTY Revvity Inc. compare | $2.6B |
| CRL Charles River Laboratories International, Inc. compare | $2.4B |
| QGEN QIAGEN N.V. | $1.6B |
| GH Guardant Health, Inc. compare | $1.5B |
| RDNT RadNet, Inc. compare | $1.3B |
| MEDP Medpace Holdings, Inc. compare | $163.0M |
| BLLN BillionToOne, Inc. compare | $89.1M |
| GRAL GRAIL, Inc. compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on QGEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement